Results 251 to 260 of about 152,178 (350)

Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study. [PDF]

Therap Adv Gastroenterol
Narita Y, Kumanishi R, Takahashi K, Masuishi T, Taniguchi H, Kadowaki S, Honda K, Ando M, Fukui T, Tajika M, Muro K.   +10 more
europepmc   +1 more source

Assessing the radiation-induced bystander effect in radionuclide therapy using targeted radiopharmaceuticals. [PDF]

EJNMMI Radiopharm Chem
Sharma R, Mukherjee A, Jagasia P, Singh SK.   +3 more
europepmc   +1 more source

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model

, 2013
Yoriko Yamashita‐Kashima, Sei Shu, Naoki Harada, Kaori Fujimoto-Ouchi   +3 more
openalex   +2 more sources

Significant efficacy of trastuzumab emtansine in HER2-positive relapsed mammary Paget's disease: a case report and literature review. [PDF]

Discov Oncol
Li W, Chen H, Wen H, Ren S, Ou C, Huang J, Zhu Y, Zhang Y.   +7 more
europepmc   +1 more source

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

, 2016
Josimar O. Eloy, Raquel Petrilli, Robert W. Brueggemeier, Juliana Maldonado Marchetti, Robert J. Lee   +4 more
openalex   +1 more source

Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells. [PDF]

Sci Rep
Jafari S, Ostadrahimi A, Farjami A, Montazersaheb S.   +3 more
europepmc   +1 more source

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study

, 2018
Αngelos Koutras, Georgios Lazaridis, Georgia-Angeliki Koliou, George Kouvatseas, Christos Christodoulou, Dimitrios Pectasides, Vassiliki Kotoula, Anna Batistatou, Mattheos Bobos, Eleftheria Tsolaki, Kyriaki Papadopoulou, George Pentheroudakis, Pavlos Papakostas, Stavroula Pervana, Kalliopi Petraki, Sofia Chrisafi, Evangelia Razis, Amanda Psyrri, Dimitrios Bafaloukos, Konstantine T. Kalogeras, Haralabos P. Kalofonos, George Fountzilas   +21 more
openalex   +2 more sources

Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. [PDF]

Breast Cancer Res
Bhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M.   +17 more
europepmc   +1 more source

Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China. [PDF]

PeerJ
Zhi L, Huang L, Pang X, Wu Q, Lei Y.
europepmc   +1 more source

Trastuzumab Decreases the Expression of G1/S Regulators and Syndecan-4 Proteoglycan in Human Rhabdomyosarcoma [PDF]

Diána Szabó, Enikő Tóth, Kitti Szabó, Zsófia Hegedüs, Noémi Bózsity, István Zupkó, László Rovó, Xue Xiao, Lin Xu, Anikó Keller-Pintér   +9 more
openalex   +1 more source